1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Vascular Dysfunction - Pipeline Review, H2 2013

Vascular Dysfunction - Pipeline Review, H2 2013

  • November 2013
  • -
  • Global Markets Direct
  • -
  • 35 pages

Vascular Dysfunction - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Vascular Dysfunction - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Vascular Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vascular Dysfunction. Vascular Dysfunction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Vascular Dysfunction.
- A review of the Vascular Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Vascular Dysfunction pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Vascular Dysfunction.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Vascular Dysfunction pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Vascular Dysfunction - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vascular Dysfunction Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Vascular Dysfunction 7
Vascular Dysfunction Therapeutics under Development by Companies 9
Vascular Dysfunction Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Vascular Dysfunction Therapeutics - Products under Development by Companies 14
Vascular Dysfunction Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Vascular Dysfunction Therapeutics Development 16
GlaxoSmithKline plc 16
Merck and Co., Inc. 17
Vascular Dysfunction - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
TXA-127 - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
BQ-123 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
caffeic acid phenethyl ester - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
trehalose - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
GI-254023X - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Vascular Dysfunction Therapeutics - Drug Profile Updates 30
Vascular Dysfunction Therapeutics - Dormant Products 32
Vascular Dysfunction - Product Development Milestones 33
Featured News and Press Releases 33
Nov 16, 2012: Bio3 Research Receives Hong Kong Patent For HMGB1 Antibodies To Treat Vascular Diseases 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35



List of Tables

Number of Products Under Development for Vascular Dysfunction, H2 2013 7
Products under Development for Vascular Dysfunction - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Clinical Stage Development, H2 2013 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 15
GlaxoSmithKline plc, H2 2013 16
Merck and Co., Inc., H2 2013 17
Assessment by Monotherapy Products, H2 2013 18
Assessment by Stage and Route of Administration, H2 2013 20
Assessment by Stage and Molecule Type, H2 2013 22
Vascular Dysfunction Therapeutics - Drug Profile Updates 30
Vascular Dysfunction Therapeutics - Dormant Products 32



List of Figures

Number of Products under Development for Vascular Dysfunction, H2 2013 7
Products under Development for Vascular Dysfunction - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Products under Investigation by Universities/Institutes, H2 2013 10
Mid Clinical Stage Products, H2 2013 11
Early Clinical Stage Products, H2 2013 12
Discovery and Pre-Clinical Stage Products, H2 2013 13
Assessment by Monotherapy Products, H2 2013 18
Assessment by Route of Administration, H2 2013 19
Assessment by Stage and Route of Administration, H2 2013 20
Assessment by Molecule Type, H2 2013 21
Assessment by Stage and Molecule Type, H2 2013 22



Companies Mentioned

GlaxoSmithKline plc
Merck and Co., Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glutamyl Aminopeptidase ...

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) ...

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘NADPH ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.